Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.
The analysis highlights Adverse effects, Mechanism of action and Clinical trials as prominent areas in the source structure around Afatinib.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Explore different angles and find fresh ideas to shape your next piece of content.
Search suggestions related to this topic. Open a question to research it further; suggestions are not verified answers.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
You can skip this section if you’re here for content ideas and keyword inspiration.
The extracted context around Afatinib shows recurring relationship patterns in the source. For example, Afatinib → AU: S4 (Prescription only), CA: ℞-only, EU: Rx-only, UK: POM (Prescription only), US: ℞-only Another extracted example is Afatinib → EGFR, Her2, Like, T790M, TKIs. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
egfr nsclc phase breast iii drug lung mutations epidermal growth factor receptor used drugs protein name gilotrif mouth cancer cancers
TTTA extracted 41 structured relationships around Afatinib. Examples in this analysis include Afatinib → 3D model (JSmol) → Interactive image and Afatinib → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Afatinib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Afatinib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Afatinib | ATC code | L01EB03 (WHO) | 1.00 | infobox |
| Afatinib | CAS Number | 850140-72-6 Y[Drugbank] | 1.00 | infobox |
| Afatinib | ChEBI | CHEBI:61390 Y | 1.00 | infobox |
| Afatinib | ChEMBL | ChEMBL1173655 Y | 1.00 | infobox |
| Afatinib | ChemSpider | 8360155 Y | 1.00 | infobox |
| Afatinib | CompTox Dashboard (EPA) | DTXSID20893451 | 1.00 | infobox |
| Afatinib | DrugBank | DB08916 Y | 1.00 | infobox |
| Afatinib | ECHA InfoCard | 100.239.035 | 1.00 | infobox |
| Afatinib | Elimination half-life | 37 hours | 1.00 | infobox |
| Afatinib | Excretion | Faeces (85%), urine (4%) | 1.00 | infobox |
| Afatinib | Formula | C24H25ClFN5O3 | 1.00 | infobox |
| Afatinib | IUPHAR/BPS | 5667 | 1.00 | infobox |
| Afatinib | KEGG | D09724 N | 1.00 | infobox |
| Afatinib | KEGG | as salt: D09733 N | 1.00 | infobox |
| Afatinib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Afatinib | Legal status | CA: ℞-only | 1.00 | infobox |
| Afatinib | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Afatinib | Legal status | US: ℞-only | 1.00 | infobox |
| Afatinib | Legal status | EU: Rx-only | 1.00 | infobox |
| Afatinib | License data | EU EMA: by INN | 1.00 | infobox |
| Afatinib | License data | US DailyMed: Afatinib | 1.00 | infobox |
| Afatinib | MedlinePlus | a613044 | 1.00 | infobox |
| Afatinib | Metabolism | CYP not involved | 1.00 | infobox |
| Afatinib | Molar mass | 485.94 g·mol−1 | 1.00 | infobox |
| Afatinib | Other names | BIBW 2992 | 1.00 | infobox |
| Afatinib | Pregnancy category | AU: C | 1.00 | infobox |
| Afatinib | Protein binding | 95% | 1.00 | infobox |
| Afatinib | PubChem CID | 10184653 | 1.00 | infobox |
The concept neighborhoods around Afatinib bring nearby vocabulary together. In this analysis, examples include Also, Lung and Protein. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Afatinib, one of the stronger structural bridges in this analysis connects Afatinib with Adverse effects. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Afatinib to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Adverse effects, Mechanism of action & Clinical trials, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Afatinib · EN edition · Analysis: TopicsToTalkAbout
